1
EXHIBIT 10.30
DECODE GENETICS, INC.
SERIES A PREFERRED STOCK REPURCHASE AGREEMENT
This Series A Preferred Stock Repurchase Agreement ("Agreement") is made
effective as of July 12, 1999 by and between deCODE genetics, Inc., a Delaware
corporation (the "Company"), and the holders of Series A Preferred Stock of the
Company listed on Exhibit A hereto (the "Sellers").
PRELIMINARY STATEMENTS
A. The Sellers are the owners of certain shares of the Company's Series A
Preferred Stock (the "Series A Stock").
B. Each Seller wishes to sell to the Company, and the Company wishes to
purchase from each Seller, the number of shares of Series A Stock set forth
opposite the Seller's name on Exhibit A hereto or such other number as may be
agreed upon by such Seller and the Company (the "Shares").
NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as
follows:
1. SALE AND PURCHASE OF THE SHARES.
1.1 Sale and Purchase. Subject to the terms and conditions hereof,
each Seller agrees to sell, and the Company agrees to purchase, the Shares for a
purchase price of Seven Dollars and Fifty Cents ($7.50) per share.
1.2 Payment for Shares. Following execution and delivery of this
Agreement by the Company and a Seller, the Company shall pay the purchase price
of the Shares to be sold to the Company by such Seller by check or wire transfer
to such account as such Seller shall designate.
1.3 Delivery of Certificates. Upon full payment by the Company of the
purchase price of its Shares, each Seller will deliver to the Company one or
more certificates representing the Shares. In the event that less than all of
the shares represented by a certificate are repurchased, the Company will
deliver to the Seller a new certificate representing the unpurchased shares.
Notwithstanding the foregoing, from and after payment by the Company as provided
in Section 1.2 hereof, all rights of the Seller as a holder of the Shares shall
cease and terminate.
2. REPRESENTATIONS OF THE SELLERS.
Each Seller hereby represents and warrants to the Company as follows:
2
2.1 Power and Authority. It has full power and authority to sell the
Shares and to enter into and perform this Agreement and any other agreements and
instruments to be executed and delivered herewith, and such sale and such
agreements (i) have been duly authorized, (ii) are legal, valid, binding and
enforceable against such Seller and (iii) are not in contravention of any law,
order or agreement by which such Seller is bound.
2.2 Title. It has made no prior assignment of the Shares or of any
interest therein. It is the sole legal and beneficial owner of the Shares and
has good and marketable title thereto, free and clear of all liens, claims and
encumbrances of any kind, and will transfer to the Company such good and
marketable title, free and clear of any liens, claims and encumbrances of any
kind.
2.3 Company Information. It is a sophisticated seller with respect to
the Shares, has adequate information concerning the business and financial
condition of the Company to make an informed decision regarding the sale of the
Shares, and has independently, without reliance upon the Company (other than
reliance upon the representations and warranties of the Company set forth
herein) and based on such information as it deemed appropriate, made its own
analysis and decision to enter into this Agreement, and such Seller acknowledges
and agrees that the Company may possess material information with respect to the
Company not known to such Seller ("Company Information"), that such Seller has
not requested the Company Information and that the Company shall have no
liability to such Seller with respect to the nondisclosure of the Company
Information and such Seller hereby releases the Company therefrom.
3. REPRESENTATIONS OF THE COMPANY.
The Company hereby represents and warrants to the Sellers that it has
full power and authority to purchase the Shares and to enter into and perform
this Agreement and any other agreements and instruments to be executed and
delivered herewith, and such purchase and such agreements (i) have been duly
authorized, (ii) are legal, valid, binding and enforceable against the Company
and (iii) are not in contravention of any law, order or agreement by which the
Company is bound.
4. MISCELLANEOUS.
4.1 Governing Law. This Agreement shall be governed by and construed
under the laws of the State of Delaware as applied to agreements among Delaware
residents made and to be performed entirely within the State of Delaware.
4.2 Binding Effect; Successors and Assigns. This Agreement shall be
deemed to be an agreement between the Company and each of the Sellers and shall
be binding upon each Seller executing the Agreement without regard to whether
any other Seller shall have executed the Agreement. Except as otherwise
expressly provided herein, the provisions hereof shall inure to the benefit of,
and be binding upon, the successors, assigns, heirs, executors, and
administrators of the parties hereto.
2
3
4.3 Entire Agreement. This Agreement constitutes the full and entire
understanding and agreement among the parties with regard to the subject matter
hereof.
4.4 Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument.
4.5 Further Action. Each party shall, without further consideration,
take such further action and execute and deliver such further documents as may
be reasonably requested by any other party in order to carry out the provisions
and purposes of this Agreement.
* * *
This Series A Preferred Stock Repurchase Agreement is hereby executed as of the
date first above written.
deCODE genetics, Inc.
By: /s/ Xxxx Xxxxxxxxxx
-----------------------------------
Xxxx Xxxxxxxxxx, President
3
4
ALTA CALIFORNIA PARTNERS, L.P.
By: Alta California Management
Partners, L.P.
By: /s/ Xxx Xxxxx
-------------------------------------------------
Name: Xxx Xxxxx
-------------------------------------------------
Title General Partner
-------------------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
Xxx Xxxxxxxxxxx Xxxxxx, Xxxxx 0000
Xxx Xxxxxxxxx, XX 00000
Facsimile: (000) 000-0000
ALTA EMBARCADERO PARTNERS, LLC
By: /s/ Xxxxxx XxXxxxxx
------------------------------------------------
Name: Xxxxxx XxXxxxxx
------------------------------------------------
Title Member
------------------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
Xxx Xxxxxxxxxxx Xxxxxx, Xxxxx 0000
Xxx Xxxxxxxxx, XX 00000
Facsimile: (000) 000-0000
4
5
ARCH VENTURE FUND II, L.P.
By: ARCH Management Partners II, L.P.,
Its General Partner
By: ARCH Venture Partners, L.P.,
Its General Partner
By: ARCH Venture Corporation,
Its General Partner
By: /s/ Xxxxx Xxxxxxxx
------------------------------------
Name: Xxxxx Xxxxxxxx
------------------------------------
Title Managing Director
------------------------------------
Address:
Attention: Xxxxxxx Xxxxx
0000 X. Xxxxxxx
Xxxxx 000
Xxxxxxx, XX 00000
Facsimile: (000) 000-0000
5
6
ATLAS VENTURE FUND II, L.P.
By: Atlas Venture Associates II, L.P.
By: /s/ Xxxx-Xxxxxxxx Xxxxxxx
---------------------------------------------
Name: Xxxx-Xxxxxxxx Xxxxxxx
---------------------------------------------
Title General Partner
---------------------------------------------
Address:
000 Xxxxxxxx Xxxxxx, Xxxxx 0000
Xxxxxx, XX 00000
Facsimile: (000) 000-0000
ATLAS VENTURE EUROPE FUND B.V.
By: /s/ Johan Xxxxxxx Xxxxxx
--------------------------------------------
Name: X. X. Xxxxxx
--------------------------------------------
Title CFO
--------------------------------------------
Address:
Xxxxxxxxxxxx 0
0000 XX Xxxxxxx
Xxx Xxxxxxxxxxx
Facsimile: 31 35 695 4888
6
7
FALCON TECHNOLOGY PARTNERS II, L.P.
A Delaware Limited Partnership
By: Falcon Technology Management Corporation
A Delaware Corporation,
Its General Partner
By: /s/ Xxxxx Xxxxxxx
------------------------------------------------
Name: Xxxxx X. Xxxxxxx
------------------------------------------------
Title President
------------------------------------------------
Address:
000 Xxxxxx Xx.
Xxxxx, XX 00000
7
8
MEDICAL SCIENCE PARTNERS II, L.P.
By: Medical Science Ventures II, L.P.
By: /s/ Xxxxxx X. Xxxxxx
------------------------------------------------
Name: Xxxxxx X. Xxxxxx
------------------------------------------------
Title General Partner
------------------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
00 Xxxxxxx Xxxxxx, Xxxxx 000
Xxxxxxxxx, XX 00000
Facsimile: (000) 000-0000
MEDICAL SCIENCE II CO-INVESTMENT, L.P.
By: Medical Science Ventures II, L.P.
By: /s/ Xxxxxx X. Xxxxxx
------------------------------------------------
Name: Xxxxxx X. Xxxxxx
------------------------------------------------
Title General Partner
------------------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
c/o Medical Science Partners
00 Xxxxxxx Xxxxxx, Xxxxx 000
Xxxxxxxxx, XX 00000
Facsimile: (000) 000-0000
8
9
UEMCO XI LIMITED PARTNERSHIP
By: /s/ Xxxxxx X. Xxxxxx
------------------------------------------------
Name: Xxxxxx X. Xxxxxx
------------------------------------------------
Title General Partner
------------------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
c/o Medical Science Partners
00 Xxxxxxx Xxxxxx, Xxxxx 000
Xxxxxxxxx, XX 00000
Facsimile: (000) 000-0000
EAGLE CONSTELLATION FUND LTD.
By: /s/ Xxxxxx X. Xxxxxx
------------------------------------------------
Name: Xxxxxx X. Xxxxxx
------------------------------------------------
Title General Partner
------------------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
c/o Medical Science Partners
00 Xxxxxxx Xxxxxx, Xxxxx 000
Xxxxxxxxx, XX 00000
Facsimile: (000) 000-0000
9
10
BEACON HILL FINANCIAL
By: /s/ X.X. Xxxxxxxx
----------------------------------------------
Name: Xxxxxx X. Xxxxxxxx
----------------------------------------------
Title President
----------------------------------------------
Address:
Attention: Xxxxxx Xxxxxxx
00 Xxx Xxxxxx
Xxxxxxxx, XX 00000
Facsimile: (000) 000-0000
10
11
NORAM TRUST
By: /s/ Xxxxx Xxxxxx
---------------------------------------------
Name: Xxxxx Xxxxxx
---------------------------------------------
Title Trustee
---------------------------------------------
Address:
c/o Windels, Marx, Davies, Ives
Attention: Xxxxx X. Xxxxxx
000 Xxxx 00xx Xxxxxx
Xxx Xxxx, XX 00000
Facsimile: (000) 000-0000
11
12
XX-XXXXXX INVESTMENT COMPANY
By: /s/ Mhd. Xxxxx Xx-Xxxxxx
------------------------------------------------
Name: Mhd. Xxxxx Xx-Xxxxxx
------------------------------------------------
Title Director
------------------------------------------------
Address:
x/x Xxx. Xxxxx Xx-Xxxxxx
Xx-Xxxxx Xxxx, Xxxx 0
P.O. Box 40761
Xxxxxx 00000, Xxxxx Xxxxxx
Facsimile: 011-966-1-495-5488
12
13
GUTRAFIN LTD.
By: /s/ X.X. Xxxx
----------------------------------------------
Name: X.X. Xxxx
----------------------------------------------
Title: Senior Investment Representative
----------------------------------------------
Address:
00 Xxxxxxx Xxxxxxxx
Xxxxxx XX0 00X
Great Britain
13
14
POLARIS VENTURE PARTNERS, L.P.
By: Polaris Venture Management co., LLC,
Its General Partner
By: /s/ Xxxx X. Xxxxxx
------------------------------------------------
Name: Xxxx X. Xxxxxx
------------------------------------------------
Title Member
------------------------------------------------
Address:
000 Xxxxxx Xxxxxx
Xxxxx 0000
Xxxxxxx, XX 00000
Facsimile: (000) 000-0000
POLARIS VENTURE FOUNDERS' FUND, L.P.
By: Polaris Venture Management co., LLC
Its General Partner
By: /s/ Xxxx X. Xxxxxx
------------------------------------------------
Name: Xxxx X. Xxxxxx
------------------------------------------------
Title Member
------------------------------------------------
Address:
000 Xxxxxx Xxxxxx
Xxxxx 0000
Xxxxxxx, XX 00000
Facsimile: (000) 000-0000
14
15
ROVENT II LIMITED PARTNERSHIP
By: Advent International Limited Partnership,
General Partner
By: Advent International Corporation, General Partner
By: /s/ Xxxxx Fisherman
------------------------------------------------
Name: Xxxxx Fisherman
------------------------------------------------
Title Vice President
------------------------------------------------
Address:
c/o Advent International Corporation
00 Xxxxx Xxxxxx, 00xx Xxxxx
Xxxxxx, XX 00000
Facsimile: (000) 000-0000
ADVENT PERFORMANCE MATERIALS
LIMITED PARTNERSHIP
By: Advent International Limited Partnership,
General Partner
By: Advent International Corporation, General Partner
By: /s/ Xxxxx Fisherman
------------------------------------------------
Name: Xxxxx Fisherman
------------------------------------------------
Title Vice President
------------------------------------------------
Address:
c/o Advent International Corporation
00 Xxxxx Xxxxxx, 00xx Xxxxx
Xxxxxx, XX 00000
Facsimile: (000) 000-0000
15
16
ADVENT PARTNERS LIMITED PARTNERSHIP
By: Advent International Corporation, General Partner
By: /s/ Xxxxx Fisherman
----------------------------------------------
Name: Xxxxx Fisherman
----------------------------------------------
Title Vice President
----------------------------------------------
Address:
c/o Advent International Corporation
00 Xxxxx Xxxxxx, 00xx Xxxxx
Xxxxxx, XX 00000
Facsimile: (000) 000-0000
16
17
EXHIBIT A
SELLING STOCKHOLDERS
SERIES A SHAREHOLDER NUMBER OF %AGE NUMBER OF REDEMPTION TOTAL PROCEEDS
SHARES HELD TO BE SHARES BEING PRICE
REDEEMED REDEEMED
Advent Partners Ltd 36,972 20% 7,394 U.S.$7.50 $55,455.00
Advent Performance Materials L.L.P 520,750 20% 104,150 U.S.$7.50 $781,125.00
Rovent II Limited Partnership 1,006,088 20% 201,218 U.S.$7.50 $1,509,135.00
Alta Embarcadero Partners, LLC 67,795 20% 13,559 U.S.$7.50 $101,692.50
Alta California Partners, L.P. 2,538,557 20% 507,711 U.S.$7.50 $3,807,832.50
ARCH Venture Fund II, L.P. 781,905 20% 156,381 U.S.$7.50 $1,172,857.50
Atlas Venture Europe Fund B.v. 1,303,176 20% 260,635 U.S.$7.50 $1,954,762.50
Atlas Venture Fund II, L.P. 1,303,176 20% 260,635 U.S.$7.50 $1,954,762.50
Falcon Technology Partners II, L.P. 646,180 20% 129,236 U.S.$7.50 $969,270.00
Medical Science Partners II, L.P. 733,142 20% 146,628 U.S.$7.50 $1,099,710.00
Medical Science II Co-Investment, L.P. 198,431 20% 39,686 U.S.$7.50 $297,645.00
Xx-Xxxxxx Investment Company 5,834 20% 1,167 U.S.$7.50 $8,752.50
Beacon Hill Financial 24,617 20% 4,923 U.S.$7.50 $36,922.50
Gutrafin Ltd. 500,000 20% 100,000 U.S.$7.50 $750,000.00
Noram Trust 6,666 20% 1,333 U.S.$7.50 $9,997.50
Eagle Constellation Fund Ltd. 11,564 20% 2,313 U.S.$7.50 $17,347.50
UEMCO XI Limited Partnership 11,753 20% 2,351 U.S.$7.50 $17,632.50
Polaris Venture Partners Founders' Fund, 115,201 20% 23,040 U.S.$7.50 $172,800.00
L.P.
Polaris Venture Partners L.P. 1,978,568 20% 395,714 U.S.$7.50 $2,967,855.00
TOTAL OF PREFERRED A-STOCK: 11,790,375 20% 2,358,074 U.S.$7.50 $17,685,555.00
17
18
DECODE GENETICS, INC.
ADDENDUM TO
SERIES A PREFERRED STOCK REPURCHASE AGREEMENT
This Addendum to Series A Preferred Stock Repurchase Agreement (this
"Addendum") is made effective as of March 1, 2000 (the "Effective Date") by and
between deCODE genetics, Inc., a Delaware corporation (the "Company"), and the
holders of Series A Preferred Stock of the Company listed on Exhibit A hereto
(the "Sellers").
PRELIMINARY STATEMENTS
A. The Company and the Sellers entered into a Series A Preferred Stock
Repurchase Agreement, dated July 12, 1999 (the "Series A Repurchase Agreement"),
pursuant to which the Corporation repurchased, in the aggregate, 2,358,074
shares (the "Series A Shares") of the Corporation's Series A Preferred Stock
from the Sellers at a closing held on August 11, 1999 (the "Closing Date").
B. It was the understanding among the Company and the Sellers that the
purchase price for the Series A Shares would be equal to the price per share,
net of commissions and other fees payable to the purchaser (the "Purchaser"), at
which the Company sold shares of its Series B Preferred Stock pursuant to a
stock purchase agreement dated as of June 30, 1999 (the "Series B Offering").
C. Contemporaneously with the execution of the Series A Repurchase
Agreement, the Company and the Sellers entered into an oral agreement that if
any contingent portion of the purchase price in the Series B Offering became
payable, the purchase price for the Series A Shares would be adjusted upward
accordingly, with the amount of such adjustment to be paid to the Sellers by the
Company after such contingent portion of the purchase price in the Series B
Offering became payable.
D. The Company and the Purchaser have entered into an Addendum to Stock
Purchase Agreement confirming that on December 28, 1999, they agreed that a
contingent payment of $7.50, less commissions and other fees payable to the
Purchaser in an amount equal to seven percent (7%) of the sum of the original
purchase price and the contingent payment, was due and payable.
NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as
follows:
1. ADJUSTMENT TO PURCHASE PRICE; PAYMENT OF DEFICIENCY. The adjusted
purchase price for the Series A Shares as of the Closing Date is US$13.95 per
share. Within five business days of the Effective Date, the Company shall pay,
by check or wire transfer to such account as such Seller shall designate,
US$6.45 (representing the adjusted purchase price of US$13.95 less the US$7.50
already paid) for each of the Series A Shares sold to the Company by such Seller
under the Series A Repurchase Agreement.
1
19
2. RATIFICATION OF AMENDMENT OF AMENDED AND RESTATED INVESTORS' RIGHTS
AGREEMENT. The amendment of the Amended and Restated Investors' Rights Agreement
dated as of February 2, 1998, as amended, among the Company and certain of its
stockholders to grant the provisions of Section 2 thereof to the holders of the
Series B Preferred Stock sold in the Series B Offering is hereby ratified,
approved and confirmed.
3. MISCELLANEOUS. This Addendum shall be governed by and construed under
the laws of the State of Delaware as applied to agreements among Delaware
residents made and to be performed entirely within the State of Delaware. Except
as otherwise expressly provided herein, the provisions hereof shall inure to the
benefit of, and be binding upon, the successors, assigns, heirs, executors, and
administrators of the parties hereto. This Addendum, together with the Series A
Repurchase Agreement constitutes the full and entire understanding and agreement
among the parties with regard to the subject matter hereof. This Addendum may be
executed in any number of counterparts, each of which shall be deemed an
original and all of which together shall constitute one instrument. Except as
set forth herein, all terms of the Series A Repurchase Agreement remain
unchanged and in full force and effect.
This Addendum to Series A Preferred Stock Repurchase Agreement is hereby
executed to be effective as of the date first above written.
deCODE genetics, Inc.
Date By: /s/ Xxxx Xxxxxxxxxx
----------------------------------------
Xxxx Xxxxxxxxxx, President
2
20
ALTA CALIFORNIA PARTNERS, L.P.
By: Alta California Management
Partners, L.P.
Date: 2/24/00 By: /s/ Xxx Xxxxx
---------------------------------------------
Name: Xxx Xxxxx
---------------------------------------------
Title General Partner
---------------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
Xxx Xxxxxxxxxxx Xxxxxx, Xxxxx 0000
Xxx Xxxxxxxxx, XX 00000
Facsimile: (000) 000-0000
ALTA EMBARCADERO PARTNERS, LLC
Date: 2/24/00 By: /s/ Xxxx Xxxxxxx
---------------------------------------------
Name: Xxxx Xxxxxxx
---------------------------------------------
Title Member
---------------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
Xxx Xxxxxxxxxxx Xxxxxx, Xxxxx 0000
Xxx Xxxxxxxxx, XX 00000
Facsimile: (000) 000-0000
3
21
ARCH VENTURE FUND II, L.P.
By: ARCH Management Partners II, L.P.,
Its General Partner
By: ARCH Venture Partners, L.P.,
Its General Partner
By: ARCH Venture Corporation,
Its General Partner
Date: 2.25.00 By: /s/ Xxxxxx Xxxxxx
-------------------------------
Name: Xxxxxx Xxxxxx
-------------------------------
Title Managing Director
-------------------------------
Address:
Attention: Xxxxxxx Xxxxx
0000 X. Xxxxxxx
Xxxxx 000
Xxxxxxx, XX 00000
Facsimile: (000) 000-0000
4
22
ATLAS VENTURE FUND II, L.P.
By: Atlas Venture Associates II, L.P.
Date: By: /s/ Xxxx-Xxxxxxxx Xxxxxxx
-------------------------------------------
Name: Xxxx-Xxxxxxxx Xxxxxxx
-------------------------------------------
Title General Partner
-------------------------------------------
Address:
000 Xxxxxxxx Xxxxxx, Xxxxx 0000
Xxxxxx, XX 00000
Facsimile: (000) 000-0000
ATLAS VENTURE EUROPE FUND B.V.
Date: By: /s/ Johan Xxxxxxx Xxxxxx
-------------------------------------------
Name: X.X. Xxxxxx
-------------------------------------------
Title: Managing Director
-------------------------------------------
Address:
Xxxxxxxxxxxx 0
0000 XX Xxxxxxx
Xxx Xxxxxxxxxxx
Facsimile: 31 35 695 4888
5
23
FALCON TECHNOLOGY PARTNERS II, L.P.
A Delaware Limited Partnership
By: Falcon Technology Management Corporation
A Delaware Corporation,
Its General Partner
Date: 2/24/00 By: /s/ Xxxxx Xxxxxxx
--------------------------------------
Name: Xxxxx X. Xxxxxxx
--------------------------------------
Title President
--------------------------------------
Address:
Greystone 60
15 Highlands.
Xxxx, XX 00000
6
24
MEDICAL SCIENCE PARTNERS II, L.P.
By: Medical Science Ventures II, L.P.
Date: 2/24/00 By: /s/ Xxxxxx X. Xxxxxx
----------------------------------------
Name: Xxxxxx X. Xxxxxx
----------------------------------------
Title General Partner
----------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
000 Xxxxxxxxx Xx.
Xxxxxxxxxx, XX 00000
Facsimile:
MEDICAL SCIENCE II CO-INVESTMENT, L.P.
By: Medical Science Ventures II, L.P.
Date: By: /s/ Xxxxxx X. Xxxxxx
----------------------------------------
Name: Xxxxxx X. Xxxxxx
----------------------------------------
Title General Partner
----------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
c/o Medical Science Partners
000 Xxxxxxxxx Xx.
Xxxxxxxxxx, XX 00000
Facsimile:
7
25
UEMCO XI LIMITED PARTNERSHIP
Date: 2/24/00 By: /s/ Xxxxxx X. Xxxxxx
-------------------------------------------
Name: Xxxxxx X. Xxxxxx
-------------------------------------------
Title General Partner
-------------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
c/o Medical Science Partners
000 Xxxxxxxxx Xx.
Xxxxxxxxxx, XX 00000
Facsimile:
EAGLE CONSTELLATION FUND LTD.
Date: 2/24/00 By: /s/ Xxxxxx X. Xxxxxx
-------------------------------------------
Name: Xxxxxx X. Xxxxxx
-------------------------------------------
Title General Partner
-------------------------------------------
Address:
Attention: Xxxxxx Xxxxxx
c/o Medical Science Partners
000 Xxxxxxxxx Xx.
Xxxxxxxxxx, XX 00000
Facsimile:
8
26
BEACON HILL FINANCIAL
Date: 25/2/00 By: /s/ X.X. Xxxxxxxx
----------------------------------
Name: Xxxxxx X. Xxxxxxxx
----------------------------------
Title President
----------------------------------
Address:
Attention: Xxxxxx Xxxxxxxx
00 Xxx Xxxxxx
Xxxxxxxx, XX 00000
Facsimile: (000) 000-0000
9
27
NORAM TRUST
Date: By: /s/ Xxxxx Xxxxxx
----------------------------------
Name: Xxxxx Xxxxxx
----------------------------------
Title Trustee
----------------------------------
Address:
c/o Windels, Marx, Davies, Ives
Attention: Xxxxx X. Xxxxxx
000 Xxxx 00xx Xxxxxx
Xxx Xxxx, XX 00000
Facsimile: (000) 000-0000
10
28
XX-XXXXXX INVESTMENT COMPANY
Date: February 25, 2000 By: /s/ Mhd. Xxxxx Xx-Xxxxxx
-------------------------------------
Name: Mhd. Xxxxx Xx-Xxxxxx
-------------------------------------
Title Director
-------------------------------------
Address:
x/x Xxx. Xxxxx Xx-Xxxxxx
Xx-Xxxxx Xxxx, Xxxx 0
P.O. Box 40761
Xxxxxx 00000, Xxxxx Xxxxxx
Facsimile: 011-966-1-495-5488
11
29
GUTRAFIN LTD.
Date: 25 Feb 2000 By: /s/ X.X. Xxxx
--------------------------------------
Name: X.X. Xxxx
--------------------------------------
Title: Senior Investment Representative
--------------------------------------
Address:
00 Xxxxxxx Xxxxxxxx
Xxxxxx XX0 00X
Great Britain
12
30
POLARIS VENTURE PARTNERS, L.P.
By: Polaris Venture Management co., LLC,
Its General Partner
Date: By: /s/ Xxxxxxxx XxXxxxx
-------------------------------------
Name:
-------------------------------------
Title
-------------------------------------
Address:
000 Xxxxxx Xxxxxx
Xxxxx 0000
Xxxxxxx, XX 00000
Facsimile: (000) 000-0000
POLARIS VENTURE FOUNDERS' FUND, L.P.
By: Polaris Venture Management co., LLC
Its General Partner
Date: By: /s/ Xxxxxxxx XxXxxxx
-------------------------------------
Name:
-------------------------------------
Title
-------------------------------------
Address:
000 Xxxxxx Xxxxxx
Xxxxx 0000
Xxxxxxx, XX 00000
Facsimile: (000) 000-0000
13
31
ROVENT II LIMITED PARTNERSHIP
By: Advent International Limited Partnership,
General Partner
By: Advent International Corporation, General Partner
Date: 2/24/00 By: /s/ Xxxxx Fisherman
-------------------------------------------
Name: Xxxxx Fisherman
-------------------------------------------
Title Vice President
-------------------------------------------
Address:
c/o Advent International Corporation
00 Xxxxx Xxxxxx, 00xx Xxxxx
Xxxxxx, XX 00000
Facsimile: (000) 000-0000
ADVENT PERFORMANCE MATERIALS
LIMITED PARTNERSHIP
By: Advent International Limited Partnership,
General Partner
By: Advent International Corporation, General Partner
Date: 2/24/00 By: /s/ Xxxxx Fisherman
-------------------------------------------
Name: Xxxxx Fisherman
-------------------------------------------
Title Vice President
-------------------------------------------
Address:
c/o Advent International Corporation
00 Xxxxx Xxxxxx, 00xx Xxxxx
Xxxxxx, XX 00000
Facsimile: (000) 000-0000
14
32
ADVENT PARTNERS LIMITED PARTNERSHIP
By: Advent International Corporation, General Partner
Date: 2/24/00 By: /s/ Xxxxx Fisherman
-------------------------------------------
Name: Xxxxx Fisherman
-------------------------------------------
Title Vice President
-------------------------------------------
Address:
c/o Advent International Corporation
00 Xxxxx Xxxxxx, 00xx Xxxxx
Xxxxxx, XX 00000
Facsimile: (000) 000-0000
15
